Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study

Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study

Summary: Background: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg IV fixed dose in April 2021. The aims...

Full description

Bibliographic Details
Main Authors: Sophie Stukas, George Goshua, Angus Kinkade, Rebecca Grey, Gregory Mah, Catherine M. Biggs, Shahin Jamal, Sonny Thiara, Tim T.Y. Lau, Jolanta Piszczek, Nilu Partovi, David D Sweet, Agnes Y.Y. Lee, Cheryl L. Wellington, Mypinder S. Sekhon, Luke Y.C. Chen
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:The Lancet Regional Health. Americas
Subjects:
Tocilizumab
Interleukin-6
COVID-19
Covid cytokine storm
Cost-effectiveness
Online Access:http://www.sciencedirect.com/science/article/pii/S2667193X2200045X

Internet

http://www.sciencedirect.com/science/article/pii/S2667193X2200045X

Similar Items